Benzinga | Nov 8, 2021 07:22AM EST

Galmed Announces New Positive Data From Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect On Fibrosis Improvement

-- Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as early as 24 weeks, data will be presented at AASLD Late Breaker Presentations --

-- Statistically significant reductions in biomarkers associated with liver fibrosis including ALT, AST, Fib-4 and ProC-3 was also observed in ~ 50 patients --

-- Results are an early indication that higher dose of Aramchol could provide statistically and clinically meaningful effect on fibrosis in the double-blind placebo controlled regulatory part for submission of an NDA under Sub-part H--